Want to see ILMN full AI Analyst Report?
Operating Income by Segment
Shows profitability across different business units, highlighting which segments drive earnings and where there might be challenges or opportunities for growth.Illumina's Core segment shows a notable recovery in 2024, with operating income rebounding significantly after previous volatility. This aligns with the company's strategic focus on the NovaSeq X transition, which has driven strong clinical market performance. Meanwhile, Grail's operating losses have ceased, reflecting a strategic shift or operational changes. Despite challenges in research markets and China, Illumina's raised full-year outlook and expansion into multiomics suggest a positive trajectory, bolstered by robust clinical demand and successful high-throughput transitions.
Date | Core Illumina | Grail | Eliminations |
|---|---|---|---|
Sep 28, 2025 | $227.00M | $0.00 | $0.00 |
Jun 30, 2025 | $214.00M | $0.00 | $0.00 |
Mar 31, 2025 | $164.00M | $0.00 | $0.00 |
Dec 29, 2024 | $174.00M | $0.00 | $0.00 |
Sep 29, 2024 | $741.00M | $0.00 | $0.00 |
Jun 30, 2024 | $442.00M | -$2.08B | -$1.00M |
Mar 31, 2024 | $116.00M | -$227.00M | $0.00 |
Dec 31, 2023 | $33.00M | -$198.00M | $2.00M |
Oct 01, 2023 | $262.00M | -$1.01B | -$1.00M |
Jul 02, 2023 | $115.00M | -$204.00M | $1.00M |